MCID: LKM004
MIFTS: 38

Leukemia, B-Cell, Chronic

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Leukemia, B-Cell, Chronic

MalaCards integrated aliases for Leukemia, B-Cell, Chronic:

Name: Leukemia, B-Cell, Chronic 54
Chronic Lymphocytic Leukemia 74
Chronic B-Cell Leukemia 54

Classifications:



External Ids:

UMLS 74 C0023434

Summaries for Leukemia, B-Cell, Chronic

MalaCards based summary : Leukemia, B-Cell, Chronic, also known as chronic lymphocytic leukemia, is related to leukemia, chronic lymphocytic and lymphocytic leukemia, and has symptoms including fatigue, angina pectoris and edema. An important gene associated with Leukemia, B-Cell, Chronic is ATM (ATM Serine/Threonine Kinase). The drugs rituximab and Adenosine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Leukemia, B-Cell, Chronic

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Leukemia, B-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 12.1
2 lymphocytic leukemia 10.3
3 leukemia, chronic lymphocytic 2 10.3
4 leukemia 10.2
5 hairy cell leukemia 10.1
6 retinoblastoma 9.9
7 lymphoid leukemia 9.9
8 purpura 9.9
9 myeloid leukemia 9.9

Graphical network of the top 20 diseases related to Leukemia, B-Cell, Chronic:



Diseases related to Leukemia, B-Cell, Chronic

Symptoms & Phenotypes for Leukemia, B-Cell, Chronic

UMLS symptoms related to Leukemia, B-Cell, Chronic:


fatigue, angina pectoris, edema, chest pain

Drugs & Therapeutics for Leukemia, B-Cell, Chronic

Drugs for Leukemia, B-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 612)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
4
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 439693 40926
5
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
8
ofatumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 679818-59-8 6918251
9
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
10
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
11
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 58-05-9 143 6006
12
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
16
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
17
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 59-30-3 6037
19
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
20 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
27 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
36 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
37 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Vitamin B9 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
41 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
48 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1792)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
6 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
7 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
8 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
9 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
10 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
11 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
12 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
13 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
14 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
15 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
16 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
19 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
20 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
21 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
22 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
23 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
24 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
25 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
26 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
27 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
28 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
29 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
30 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
31 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
32 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
33 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
34 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
35 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
36 Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01659021 Phase 3 Idelalisib;Ofatumumab
37 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
38 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
39 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
40 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
41 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
42 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
43 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
44 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
45 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
46 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
47 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3 Fludarabine mono
48 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
49 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
50 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3

Search NIH Clinical Center for Leukemia, B-Cell, Chronic

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Leukemia, B-Cell, Chronic

Anatomical Context for Leukemia, B-Cell, Chronic

MalaCards organs/tissues related to Leukemia, B-Cell, Chronic:

42
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Kidney, Nk Cells

Publications for Leukemia, B-Cell, Chronic

Articles related to Leukemia, B-Cell, Chronic:

(show top 50) (show all 5630)
# Title Authors Year
1
Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia. ( 31029024 )
2019
2
Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax. ( 31106622 )
2019
3
Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia. ( 30899641 )
2019
4
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). ( 31102420 )
2019
5
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. ( 30458196 )
2019
6
The t(11;14)(q13;q32)/CCND1-IGH translocation in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an unusual genetic aberration during natural clinical course. ( 31021442 )
2019
7
Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. ( 30650954 )
2019
8
Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 30155841 )
2019
9
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. ( 30187496 )
2019
10
Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. ( 30316899 )
2019
11
Unilateral granuloma annulare in association with pyoderma gangrenosum and chronic lymphocytic leukemia. ( 30982302 )
2019
12
Hairy cell leukemia coexistent with chronic lymphocytic leukemia. ( 30872271 )
2019
13
Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. ( 30719361 )
2019
14
Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. ( 30792201 )
2019
15
Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature. ( 31091174 )
2019
16
Atypical presentation of cutaneous herpes simplex virus in a patient with chronic lymphocytic leukemia. ( 30726479 )
2019
17
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era. ( 31099686 )
2019
18
Study of gene expressions' correlation structures in subgroups of Chronic Lymphocytic Leukemia Patients. ( 31108207 )
2019
19
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. ( 31111763 )
2019
20
Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. ( 31066214 )
2019
21
Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL). ( 31069011 )
2019
22
PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. ( 31073371 )
2019
23
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. ( 31074316 )
2019
24
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. ( 31076448 )
2019
25
A rare case of atypical chronic lymphocytic leukemia presenting as acute kidney injury. ( 31079599 )
2019
26
Overlapped differentially expressed genes between acute lymphoblastic leukemia and chronic lymphocytic leukemia revealed potential key genes and pathways involved in leukemia. ( 31081970 )
2019
27
PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. ( 31084779 )
2019
28
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. ( 31088809 )
2019
29
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. ( 31089249 )
2019
30
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. ( 31092457 )
2019
31
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. ( 31097627 )
2019
32
Responsiveness of Chronic Lymphocytic Leukemia cells to B cell receptor stimulation is associated with low expression of regulatory molecules of the Nuclear Factor-κB pathway. ( 31097630 )
2019
33
The influence of MTHFR C677T polymorphism in Chronic Lymphocytic Leukemia. ( 31020666 )
2019
34
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. ( 31023700 )
2019
35
Hodgkin lymphoma transformation of chronic lymphocytic leukemia - a real life data from the Polish Lymphoma Research Group. ( 31026087 )
2019
36
Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. ( 31027992 )
2019
37
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in Chronic Lymphocytic Leukemia. ( 31044428 )
2019
38
Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. ( 31048356 )
2019
39
CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. ( 31049958 )
2019
40
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience. ( 31054420 )
2019
41
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. ( 31055248 )
2019
42
Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. ( 31055788 )
2019
43
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins. ( 30988120 )
2019
44
Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia. ( 30988562 )
2019
45
Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia. ( 30988580 )
2019
46
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. ( 30995176 )
2019
47
Application of an Artificial Neural Network in the Diagnosis of Chronic Lymphocytic Leukemia. ( 31001458 )
2019
48
Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. ( 31004028 )
2019
49
Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. ( 31004033 )
2019
50
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. ( 31005650 )
2019

Variations for Leukemia, B-Cell, Chronic

Expression for Leukemia, B-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, B-Cell, Chronic.

Pathways for Leukemia, B-Cell, Chronic

GO Terms for Leukemia, B-Cell, Chronic

Sources for Leukemia, B-Cell, Chronic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....